DK2349346T3 - Fremgangsmåde til metronomisk dosering med campothecinprodrugs - Google Patents

Fremgangsmåde til metronomisk dosering med campothecinprodrugs Download PDF

Info

Publication number
DK2349346T3
DK2349346T3 DK09789364.8T DK09789364T DK2349346T3 DK 2349346 T3 DK2349346 T3 DK 2349346T3 DK 09789364 T DK09789364 T DK 09789364T DK 2349346 T3 DK2349346 T3 DK 2349346T3
Authority
DK
Denmark
Prior art keywords
campothecin
prodrugs
metronomic dosing
metronomic
dosing
Prior art date
Application number
DK09789364.8T
Other languages
Danish (da)
English (en)
Inventor
Michael A Eldon
Shibani S Harite
Tamra L Barker
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Application granted granted Critical
Publication of DK2349346T3 publication Critical patent/DK2349346T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK09789364.8T 2008-09-23 2009-09-23 Fremgangsmåde til metronomisk dosering med campothecinprodrugs DK2349346T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9951608P 2008-09-23 2008-09-23
US10693108P 2008-10-20 2008-10-20
US17343309P 2009-04-28 2009-04-28
PCT/US2009/005284 WO2010036335A1 (en) 2008-09-23 2009-09-23 Compositions and methods for achieving sustained therapeutic drug concentrations in a subject

Publications (1)

Publication Number Publication Date
DK2349346T3 true DK2349346T3 (da) 2019-10-07

Family

ID=41268391

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09789364.8T DK2349346T3 (da) 2008-09-23 2009-09-23 Fremgangsmåde til metronomisk dosering med campothecinprodrugs

Country Status (21)

Country Link
US (3) US8906353B2 (enExample)
EP (1) EP2349346B1 (enExample)
JP (3) JP2012503602A (enExample)
KR (1) KR20110063457A (enExample)
CN (1) CN102164617A (enExample)
AU (1) AU2009297091B2 (enExample)
CA (1) CA2736939C (enExample)
CY (1) CY1122208T1 (enExample)
DK (1) DK2349346T3 (enExample)
ES (1) ES2744975T3 (enExample)
HR (1) HRP20192120T1 (enExample)
HU (1) HUE047352T2 (enExample)
IL (1) IL211888A (enExample)
LT (1) LT2349346T (enExample)
MX (1) MX2011003063A (enExample)
PL (1) PL2349346T3 (enExample)
PT (1) PT2349346T (enExample)
RS (1) RS59607B1 (enExample)
SI (1) SI2349346T1 (enExample)
SM (1) SMT201900609T1 (enExample)
WO (1) WO2010036335A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011003063A (es) 2008-09-23 2011-04-21 Nektar Therapeutics Composiciones y metodos para lograr concentraciones terapeuticas de farmaco sostenidas en un individuo.
US9359376B2 (en) * 2011-04-08 2016-06-07 Sphaera Pharma Pte. Ltd Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
CN104813167B (zh) * 2012-11-28 2019-04-09 尼克塔治疗公司 用于评估和预测用一种长效拓扑异构酶i抑制剂进行乳腺癌治疗的疗效的方法
EP3258913A1 (en) * 2015-02-17 2017-12-27 Mallinckrodt Nuclear Medicine LLC Modified docetaxel liposome formulations and uses thereof
AU2017273495B2 (en) 2016-06-02 2023-01-12 Innopharmax, Inc. Metronomic oral gemcitabine for cancer therapy
CN106539557A (zh) * 2016-10-08 2017-03-29 西安交通大学 一种基于恒速静脉输入的药代动力学参数的测定方法
EP3852793B1 (en) 2018-09-17 2025-11-19 The Children's Hospital Of Philadelphia Macromolecular prodrug peg-[sn22]4
AU2022226605A1 (en) * 2021-02-23 2023-10-12 Edison Oncology Compositions and methods to improve the therapeutic benefit of suboptimally administered compounds and therapies for the treatment of diseases
CN115317486B (zh) * 2022-08-17 2024-04-19 南昌大学 一种共载紫杉醇和伊立替康前药纳米制剂及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4406793A (en) 1992-06-04 1993-12-30 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5614549A (en) 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
IL117684A (en) 1995-04-07 2002-02-10 Pharmacia & Upjohn Inc Intermediates and Process for Production of History of Kempotocin (CPT-11) and Related Compounds
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
PL189698B1 (pl) 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6111107A (en) 1997-11-20 2000-08-29 Enzon, Inc. High yield method for stereoselective acylation of tertiary alcohols
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
JP2002542304A (ja) 1999-04-28 2002-12-10 ベクトレイムド インコーポレイテッド 酵素的に活性化された重合薬物接合体
AU4564200A (en) 1999-04-29 2000-11-17 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
CA2394980C (en) 1999-12-22 2008-05-13 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
WO2001062299A2 (en) 2000-02-28 2001-08-30 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
US6629995B1 (en) 2000-03-31 2003-10-07 Super Gen, Inc. Camptothecin conjugates
DK1301810T3 (da) 2000-07-21 2009-01-26 Schlumberger Services Petrol Kernemagnetiske resonansfremgangsmåder til at uddrage information om et fluidum i en klippe
US20020182172A1 (en) 2000-11-30 2002-12-05 Shearwater Corporation Water-soluble polymer conjugates of triazine derivatives
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US7401013B2 (en) 2001-10-15 2008-07-15 Lockheed Martin Corporation Method to optimize test data
KR20050040832A (ko) 2001-10-29 2005-05-03 넥타르 테라퓨틱스 에이엘, 코포레이션 단백질 키나아제 c 억제제의 중합체 공액
DE60219677T2 (de) 2001-10-30 2008-05-15 Nektar Therapeutics Al, Corp., Huntsville Wasserlösliche polymerkonjugate von retinoesäure
AU2002346686A1 (en) * 2001-12-07 2003-06-23 Intermune, Inc. Compositions and method for treating hepatitis virus infection
US6608076B1 (en) 2002-05-16 2003-08-19 Enzon, Inc. Camptothecin derivatives and polymeric conjugates thereof
JP2005529938A (ja) 2002-06-06 2005-10-06 ユニバーシティ オブ ワシントン 癌の発症を予防または遅延するためのアルテミシニン様化合物を使用する方法
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
KR20140070676A (ko) 2002-09-06 2014-06-10 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
CN1852740B (zh) 2003-09-17 2011-05-11 耐科塔医药公司 多支链聚合物的药物前体
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
EP1989212B1 (en) 2006-02-17 2013-06-19 Cascade Prodrug Inc. Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs
MX2009008549A (es) 2007-02-09 2009-08-18 Enzon Pharmaceuticals Inc Tratamiento de canceres resistentes o refractarios con conjugados polimericos de brazos multiples de 7-etil-10-hidroxicamptotecina.
CN101199857B (zh) 2007-12-12 2011-04-13 中国药科大学 mPEG-PLA-喜树碱类药物的结合物
MX2011003063A (es) 2008-09-23 2011-04-21 Nektar Therapeutics Composiciones y metodos para lograr concentraciones terapeuticas de farmaco sostenidas en un individuo.

Also Published As

Publication number Publication date
JP2015034180A (ja) 2015-02-19
SMT201900609T1 (it) 2020-01-14
IL211888A0 (en) 2011-06-30
CY1122208T1 (el) 2020-11-25
MX2011003063A (es) 2011-04-21
PL2349346T3 (pl) 2020-03-31
IL211888A (en) 2015-08-31
US20150087668A1 (en) 2015-03-26
CA2736939C (en) 2021-09-14
SI2349346T1 (sl) 2019-12-31
US20180028525A1 (en) 2018-02-01
AU2009297091B2 (en) 2015-03-05
KR20110063457A (ko) 2011-06-10
AU2009297091A1 (en) 2010-04-01
JP2012503602A (ja) 2012-02-09
PT2349346T (pt) 2019-10-24
JP2016216510A (ja) 2016-12-22
CA2736939A1 (en) 2010-04-01
JP6076317B2 (ja) 2017-02-08
US8906353B2 (en) 2014-12-09
EP2349346B1 (en) 2019-08-28
US9801873B2 (en) 2017-10-31
HRP20192120T1 (hr) 2020-02-21
US20110269789A1 (en) 2011-11-03
LT2349346T (lt) 2019-09-25
CN102164617A (zh) 2011-08-24
RS59607B1 (sr) 2020-01-31
US10525051B2 (en) 2020-01-07
EP2349346A1 (en) 2011-08-03
HUE047352T2 (hu) 2020-04-28
WO2010036335A1 (en) 2010-04-01
ES2744975T3 (es) 2020-02-27

Similar Documents

Publication Publication Date Title
DK2739293T3 (da) Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus
DK3226459T3 (da) Udveksling af parametre relateret til måleperioder
DK3520805T3 (da) Sammensætninger til behandling af myelofibrose
DK2773779T3 (da) Fremgangsmåder og sammensætninger til diagnosticering, prognose og forebyggelse af neurologiske tilstande
EP2670846A4 (en) PROCESS FOR DEVELOPING TERPENYNTHASE VARIANTS
DK2500036T3 (da) MET-hæmmere til øgning af virkningen af radioterapi
DK2773354T3 (da) Oralformuleringer med øjeblikkelig frigivelse for substituerede quinazolinoner
EP2675909A4 (en) GLUCOSYLSTEVIA COMPOSITION
EP2720561A4 (en) Stevia-COMPOSITION
DK3192520T3 (da) Terapeutiske midler til reducering af niveauerne af parathyreoideahormon
BR302012003139S1 (pt) Configuração aplicada em relógio
EP2713762A4 (en) Stevia-COMPOSITION
DK3141548T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af azaindoler
DK2585088T3 (da) Sammensætning til forbedring af seksuel sundhed
DK3395357T3 (da) Sammensætning til kontrolleret ovariestimulering
DK2785801T4 (da) Fremgangsmåde til formindskelse af isdannelse på et underlag
DK2794655T3 (da) Fremgangsmåde til selektiv mængdebestemmelse af a-beta-aggregater
DK2627656T3 (da) Fremgangsmåde til fremstilling af dihydropteridinon og intermediater deraf
DK3382003T3 (da) Detergentsammensætninger med lipasevarianter
FI20096141A0 (fi) Lämpötilan mittausmenetelmä
EP2768515A4 (en) GLUCOSYLSTEVIA COMPOSITION
EP2722366A4 (en) CURABLE COMPOSITION
DK2554172T3 (da) Fremgangsmåde til behandling af sygdomme
LT2349346T (lt) Kamptotecino provaistų (pvz., peg-irinotekano) metronominio dozavimo būdas
SG11201403667VA (en) Analysing sequencing bias